The SAINT® neuromodulation system is an innovative approach to treating depression. It employs non-invasive magnetic stimulation tailored to precisely target specific brain areas linked to depression. This accelerated and personalized method is designed to treat Major Depressive Disorder (MDD).
5 Days
A convenient and effective accelerated treatment plan
79%
Remission rate in trial patients with severe depression.
FDA Cleared
Cleared as safe and effective
Acacia Clinics is the first independent treatment center to provide commercial SAINT® therapy developed by Magnus Medical.
Acacia is highly experienced in administering SAINT® Therapy. Since 2021, our doctors, technicians, and staff have been conducting research trials with SAINT®. Currently, Acacia is the sole provider of this therapy in Northern California.
In clinical studies, SAINT® has been shown to be effective in the treatment of MDD, with approximately 80-90% of patients achieving remission of depression symptoms following the five-day treatment protocol.
Treatment with SAINT® is safe and well-tolerated according to results, indicating that this new treatment promises to be a rapid and effective treatment for treatment-resistant major depression.
More about SAINT®
Magnus Medical, Inc. recently announced the commercial launch of the SAINT® neuromodulation system, a rapid-acting, groundbreaking therapy for treatment-resistant major depressive disorder (MDD).¹
The SAINT® Neuromodulation system has received FDA clearance, marking a significant milestone in the field of medical technology.²
According to Magnus Medical, the SAINT® Neuromodulation System “uses structural and functional magnetic resonance imaging (MRI) to inform a proprietary algorithm that identifies the optimal anatomic target for focused neurostimulation in people with MDD. This new approach is delivered on an accelerated, five-day timeline with targeting of the stimulation precisely tailored to each person’s brain connectivity.”³
According to a press release by Magnus Medical, findings show treatment with SAINT® for major depression produces changes in brain signaling by reversing the direction of abnormal brain signals bilaterally in a region called the anterior cingulate cortex (ACC). To learn more, read the article.²
1. Magnus Medical. (2024, April 30). Magnus Medical Announces Commercial Launch of Groundbreaking SAINT Neuromodulation System [Press release]. Retrieved from
https://www.magnusmed.com/press-releases/magnus-medical-announces-commercial-launch-of-groundbreaking-saint-neuromodulation-system/
2. Magnus Medical. (2022, September 6). Magnus Medical receives FDA clearance for the Saint Neuromodulation System [Press release]. Retrieved from https://www.magnusmed.com/press-releases/magnus-medical-receives-fda-clearance-for-the-saint-neuromodulation-system/
3. Magnus Medical. (2023, May 15). Magnus Medical shares new study results [Press release]. Retrieved from https://www.magnusmed.com/press-releases/magnus-medical-shares-new-study-results/
“These findings have the potential to be a game-changer. This strongly supports the role of fMRI resting-state connectivity in our SAINT® Neuromodulation System as a method of personalized targeting to treat underlying causes of depression, and suggests that this could be a fundamental biological signature of major depressive disorder.”
— Brandon Bentzley, M.D., Ph.D., Magnus New Study Results
Media
MAY 16, 2023 — ABC7
Clinical Trial Underway Locally for Potential Breakthrough with Major Depressive Disorder
Brandon Bentzley, M.D., Ph.D., co-founder, CSO, Magnus Medical speaks with ABC7 Bay Area News about SAINT™ treatment for major depression.
NOVEMBER 7, 2021 — CBS SUNDAY MORNING
A Promising New Treatment for Depression
Depression remains the leading cause of disability worldwide, affecting almost 300 million people, half of whom can't find lasting relief from drugs or therapy. But a new experimental treatment using a fast-acting approach with targeted magnetic stimulation, called SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), has achieved significant success in trials. Correspondent Lee Cowan reports.
TMS Treatments
Research Center